Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4401 participants.
Also called NCT02065791
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,401 participants
- Registry
-
NCT02065791 -
2013-004494-28
-
- Other papers using this trial's data
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
- Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
- Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
- Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes
- Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
- Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial
- Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
- Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
- Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
- Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
- Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Guatemala, Hungary, India, Japan, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02065791. Randomized; double masking; primary purpose treatment. Start 2014-02-17 (actual); primary completion 2018-10-30 (actual). Results posted on 2019-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
- Acronym
- CREDENCE
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- The George Institute for Global Health, Australia
Record details
- Record id
cardio:ct-nct02065791- Content hash
15bb054394e688ce06765647f5aa7052cb3dbb79c9e1f959939dfd657054a2b7